^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

    Excerpt:
    ...- ALK rearrangement detection method is NGS and Ventana...
    Trial ID:
    NCT03647111
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Sci Rep
    Title:

    Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement

    Published date:
    10/22/2021
    Excerpt:
    We enrolled 95 non-squamous NSCLC patients with known status of EGFR, ALK, ROS1, MET and RET genes and PD-L1 protein expression….In 32 patients with ALK or ROS1 genes rearrangements, 10 patients received crizotinib and 22 patients chemotherapy in the first-line of treatment. The median overall survival was 34 months (95% CI 9.5–34 months) in crizotinib treated patients and 6 months (95% CI 4–15.5 months) in patients who received chemotherapy (HR = 0.266, 95% CI 0.104–0.678, p = 0.0056)...
    DOI:
    https://doi.org/10.1038/s41598-021-00309-3
    Test:
    Vysis ALK Break Apart FISH Probe Kit